Klaus Gjervig Jensen

USPTO Granted Patents = 26 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 3.8

ph-index = 7

Forward Citations = 174(Granted Patents)

Location History:

Frederiksberg, DK (1987 - 1990)
Kobenhavn K, DK (2013 - 2017)
Copenhagen, DK (2010 - 2021)
Valby, DK (2020 - 2024)

Company Filing History:

Statens Serum Institut

patents

1 out of 19

Ferring International Center Sa.

patents

Years Active: 1987-2025

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421271 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR, 10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2025-09-23),

2. 12398106 - Catecholamine carbamate prodrugs for use in the treatment of parkinson's disease (2025-08-26),

3. 12391650 - Catecholamine prodrugs for use in the treatment of Parkinson's disease (2025-08-19),

4. 12384765 - Catecholamine prodrugs for use in the treatment of Parkinson's Disease (2025-08-12),

5. 12319710 - Catecholamine prodrugs for use in the treatment of Parkinson's diseases (2025-06-03),

6. 12226428 - Catecholamine prodrugs for use in the treatment of Parkinson's disease (2025-02-18),

7. 12116355 - Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia (2024-10-15),

8. 11858954 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2024-01-02),

9. 11707476 - Catecholamine prodrugs for use in the treatment of parkinson's disease (2023-07-25),

10. 11130775 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2021-09-28),

11. 11110110 - Catecholamine prodrugs for use in the treatment of Parkinson's disease (2021-09-07),

12. 11059798 - Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia (2021-07-13),

13. 10729710 - Catecholamine prodrugs for use in the treatment of Parkinson's disease (2020-08-04),

14. 10501427 - Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia (2019-12-10),

15. 10118907 - Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia (2018-11-06),

Title: Innovations in Neuropharmacology: The Patents of Klaus Gjervig Jensen

Introduction

Klaus Gjervig Jensen, based in Copenhagen, Denmark, is a prolific inventor with an impressive portfolio comprising 21 patents. His contributions to the field of neuropharmacology have been significant, exploring innovative approaches to treat neurodegenerative diseases and psychiatric disorders.

Latest Patents

Jensen's latest patents focus on groundbreaking compounds aimed at treating conditions like Parkinson's disease and schizophrenia. One of his notable inventions includes catecholamine prodrugs designed for the treatment of Parkinson's disease. This invention offers pharmaceutical compositions comprising these compounds for use in treating neurodegenerative diseases and disorders. Additionally, he has developed deuterated 1-piperazino-3-phenyl indanes, which show promise in treating schizophrenia by acting on dopamine and serotonin receptors in the central nervous system.

Career Highlights

Throughout his career, Klaus Gjervig Jensen has worked with leading companies such as H. Lundbeck A/S and Statens Serum Institut. His expertise in drug development and formulation has driven advancements in the treatment of complex psychological and neurological conditions.

Collaborations

Collaborative efforts have been pivotal in Jensen's work, with notable colleagues including Morten Jorgensen and Peter Hongaard Andersen. These partnerships have fostered a dynamic exchange of ideas, enhancing the research and development process in neuropharmacology.

Conclusion

Klaus Gjervig Jensen continues to be a significant figure in the field of innovations aimed at mental health and neurodegenerative diseases. His patents reflect a commitment to improving patient outcomes through innovative treatment solutions and collaborations within the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.